top of page
Our Pipeline
Skyhawk develops a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease.
Our wholly-owned pipeline includes programs across neurodegenerative, oncology, neuromuscular, fibrotic diseases, and other disease types. Many of our programs address targets formerly considered “undruggable” for traditional protein-targeting mechanisms.
Indication
Product Candidate
Target
Platform
Discovery
Preclinical
Phase 1/2
Pivotal
Owner
Huntington's Disease
SKY-0515
HTT
Small molecule splicing modulator
Rare Neuro
SKY-0925
Undisclosed
Small molecule splicing modulator
Rare Neuro
SKY-4100
Small molecule splicing modulator
Undisclosed
Rare Neuro
SKY-2100
Undisclosed
Small molecule splicing modulator
Platform Pipeline
Our proprietary platform has discovered additional high quality chemical matter for high-value targets in neuro/rare, broad CNS, obesity, oncology, hematology, and other indications.
Partnered Pipeline
Our confidential partnered pipeline with major Pharma includes over a dozen preclinical programs
across neurodegenerative, oncology, neuromuscular, rare and other disease types.
bottom of page